We are live on ! Find out more
ORIA

Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA

Delisted

ORIA was delisted on the 28th of April, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 49 → 0 (-49)

100% less capital invested

Capital invested by funds: $145M → $0 (-$145M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 49

Holders
–
Holders Change
-49
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
49
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
-$13.4M
2
WCMNY
Westchester Capital Management (New York)
New York
-$9.74M
3
GCL
Glazer Capital LLC
New York
-$8.7M
4
MI
MMCAP International
Cayman Islands
-$8.18M
5
FTCM
Fir Tree Capital Management
New York
-$8.1M

ORIA Hedge Fund Activity: Q2 2023 in Review

0 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q2 2023, worth a combined $0 — down 100% from $145M a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ORIA and 0 opened new positions — a net loss of 49 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Aristeia Capital, exiting entirely with an estimated $13.4M sold.

  • 0 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q2 2023, down from 49 in Q1 2023.
  • Funds reported $0 of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q2 2023 and 49 closed out, a net change of -49 holders.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q2 2023 was Aristeia Capital, an estimated $13.4M sold.

Based on aggregated 13F filings for Q2 2023.